Skip to main
LLY
LLY logo

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 44%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly reported a robust performance in the second quarter of 2025, surpassing expectations for both revenue and earnings, and subsequently raising its full-year guidance, which indicates strong operational momentum. Significant growth was noted in the sales of Mounjaro outside the United States, which increased by 60% quarter-over-quarter, fueled by new launches in emerging markets like Brazil, Mexico, and India. Additionally, the introduction of orforglipron as an oral GLP-1 therapy is anticipated to enhance the company’s product offerings, further solidifying its position in the cardiometabolic market.

Bears say

Eli Lilly's stock outlook is negatively impacted by several internal and external factors, including potential pricing and rebate pressures that could affect revenue generation across its key products. The company has experienced a disappointing prescription trajectory for its tirzepatide product, Mounjaro, alongside observed declines in Zepbound prescriptions, which are anticipated to hinder volumetric growth in the upcoming quarter. Additionally, the competitive threat posed by orforglipron, particularly in the cardiometabolic segment, along with reduced peak sales forecasts and concerns over its launch performance, contributes further to a pessimistic financial outlook for Eli Lilly.

Eli Lilly (LLY) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 44% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 16 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,075.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,075.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.